Sequential (6 month) molecular response assessment in patients who developed pleural effusions. (A) Patients who ceased dasatinib (n = 18): switched TKI (n = 10), ceased TKI (n = 8). (B) Patients who continued dasatinib (n = 17). BOS, bosutinib; DAS, dasatinib; IMAT, imatinib; NIL, nilotinib; PE, pleural effusion.